<DOC>
	<DOCNO>NCT00086996</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , oxaliplatin fluorouracil , work different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Oxaliplatin fluorouracil may make tumor cell sensitive radiation therapy may kill tumor cell . Giving chemotherapy radiation therapy surgery may shrink tumor remove . PURPOSE : This phase II trial study well give oxaliplatin together fluorouracil radiation therapy work treat patient undergo surgery stage II stage III cancer esophagus gastroesophageal junction .</brief_summary>
	<brief_title>S0356 Oxaliplatin , 5-FU , Radiation Therapy ( RT ) , Surgery Pts With Stage II III Cancer Esophagus Gastroesophageal ( GE ) Junction</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine pathologic complete response probability patient stage II III adenocarcinoma esophagus gastroesophageal junction treat neoadjuvant oxaliplatin , fluorouracil , radiotherapy follow definitive surgical resection . Secondary - Determine frequency severity toxic effect associate neoadjuvant regimen patient . - Determine overall survival progression-free survival patient treat regimen . Exploratory Analyses ( subject funding availability ) - Correlate , preliminarily , initial messenger ribonucleic acid ( mRNA ) level gene thymidylate synthase ( TS ) , γ-glutamyl transpeptidase ( γGT ) , γ-glutamyl cysteine ( γ-GCS ) , DNA excision repair cross-complementing ( ERCC-1 ) , xeroderma pigmentosum ( XPA ) response survival patient treat regimen . - Correlate , preliminarily , mRNA level TS , γGT , γ-GCS , ERCC-1 , XPA treatment regimen survival patient . - Correlate , preliminarily , specific genetic polymorphism TS ERCC-1 tumor response overall survival patient treat regimen . OUTLINE : This multicenter study . - Neoadjuvant chemoradiotherapy : Patients receive oxaliplatin IV 2 hour day 1 , 15 , 29 fluorouracil ( 5-FU ) IV continuously day 8-43 . Beginning day 8 , patient also undergo radiotherapy daily , 5 day week , 5 week . - Surgery : Patients stable disease well undergo surgical resection 4-10 week completion chemoradiotherapy . - Adjuvant chemotherapy : Beginning 4-10 week surgery , patient receive chemotherapy comprise oxaliplatin IV 2 hour day 1 , 15 , 29 5-FU IV continuously day 1-36 . Treatment continue absence unacceptable toxicity disease progression . Patients follow every 3 month 1 year every 6 month 2 year . PROJECTED ACCRUAL : A total 45-85 patient accrue study within 17-21 month .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary adenocarcinoma thoracic esophagus gastroesophageal junction No recurrent disease Primary esophageal tumor least 20 cm incisor ( &lt; 26 cm incisor , bronchoscopy must perform cytology must negative ) Esophageal disease confine esophagus periesophageal soft tissue Gastroesophageal junction disease extend ≤ 2 cm gastric cardia Clinical stage II III disease CT scan MRI If esophageal mass detect method , esophageal endoscopic ultrasound require determine stage Positronemission tomography scan require confirm stage Measurable nonmeasurable disease xray , scan , physical examination No celiac axis node ≥ 1.5 cm Measurable regional lymph node ≥ 1.5 cm station 210=N1 OR subdiaphragmatic lymph node station 1519 ≤ 1.5 cm CT scan MRI allow Palpable supraclavicular lymph node must free metastatic esophageal cancer biopsy PATIENT CHARACTERISTICS : Age Over 18 Performance status Zubrod 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 White blood cell ( WBC ) count ≥ 3,000/mm^3 Hemoglobin ≥ 10.0 g/dL ( transfusion allow ) Hepatic Albumin ≥ 3 g/dL Bilirubin normal Renal Creatinine ≤ 1.5 time upper limit normal Cardiovascular No myocardial infarction cerebrovascular event within past 6 month Pulmonary No active pneumonia inflammatory lung infiltrate Other No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix No peripheral neuropathy ≥ grade 2 Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy esophageal cancer Endocrine therapy Not specify Radiotherapy No prior radiotherapy esophageal cancer No concurrent intensitymodulated radiotherapy Surgery No prior surgical resection attempt surgical resection esophageal cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>adenocarcinoma esophagus</keyword>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
</DOC>